Verrica Pharmaceuticals Initiates Phase 3 Trial for YCANTH in Common Warts
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 4 days ago
0mins
Source: NASDAQ.COM
- Trial Initiation: Verrica Pharmaceuticals announced on Monday the dosing of the first U.S. patient in the Phase 3 COVE-3 trial for YCANTH, marking a significant advancement in treating common warts, potentially benefiting 22 million patients in the U.S.
- International Collaboration: Partner Torii Pharmaceutical initiated dosing for the first Japanese patient in the COVE-3 trial last week, indicating the global development potential of YCANTH and enhancing Verrica's competitive position in the market.
- Trial Design: The COVE-3 trial is a double-blind, randomized, vehicle-controlled study aimed at evaluating the efficacy and safety of YCANTH, following the completion of 50% enrollment in the COVE-2 trial, showcasing the company's proactive approach in clinical development.
- Funding Allocation: The trial expenses will be shared equally between Verrica and Torii, with Torii covering the first $40 million, a collaborative funding strategy that alleviates Verrica's financial burden and supports ongoing R&D efforts.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy VRCA?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on VRCA
Wall Street analysts forecast VRCA stock price to rise
4 Analyst Rating
3 Buy
1 Hold
0 Sell
Strong Buy
Current: 6.210
Low
17.00
Averages
18.67
High
20.00
Current: 6.210
Low
17.00
Averages
18.67
High
20.00
About VRCA
Verrica Pharmaceuticals Inc. is a dermatology therapeutics company developing and selling medications for skin diseases requiring medical intervention. The Company's product portfolio consists of one approved product with several potential follow-on indications, as well as an additional pipeline product. Its commercial product, YCANTH (VP-102), is a proprietary drug-device combination that contains a GMP-controlled formulation of cantharidin. YCANTH (VP-102) is being developed for the treatment of molluscum contagiosum in adult and pediatric patients two years of age and older. It is also engaged in developing YCANTH (VP-102) for a potential follow-on indication for the treatment of common warts. Its second development candidate, VP-315, is an oncolytic peptide-based injectable therapy for the potential treatment of dermatology oncologic conditions, including basal cell carcinoma (BCC).
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Verrica Pharmaceuticals Initiates Phase 3 Trial for YCANTH in Common Warts
- Trial Initiation: Verrica Pharmaceuticals announced on Monday the dosing of the first U.S. patient in the Phase 3 COVE-3 trial for YCANTH, marking a significant advancement in treating common warts, potentially benefiting 22 million patients in the U.S.
- International Collaboration: Partner Torii Pharmaceutical initiated dosing for the first Japanese patient in the COVE-3 trial last week, indicating the global development potential of YCANTH and enhancing Verrica's competitive position in the market.
- Trial Design: The COVE-3 trial is a double-blind, randomized, vehicle-controlled study aimed at evaluating the efficacy and safety of YCANTH, following the completion of 50% enrollment in the COVE-2 trial, showcasing the company's proactive approach in clinical development.
- Funding Allocation: The trial expenses will be shared equally between Verrica and Torii, with Torii covering the first $40 million, a collaborative funding strategy that alleviates Verrica's financial burden and supports ongoing R&D efforts.
See More
Verrica Advances Clinical Trials for YCANTH in U.S. and Japan
- Clinical Trial Launch: Verrica announced the dosing of the first patient in the U.S. for the second clinical trial, COVE-3, marking a significant advancement in the global Phase 3 program for YCANTH (VP-102) aimed at treating common warts, which addresses the unmet needs of approximately 22 million patients in the U.S.
- Japanese Patient Enrollment: Verrica's partner, Torii Pharmaceutical, has also dosed the first patient in Japan for the COVE-3 trial, demonstrating synchronized progress in both markets and enhancing the global market potential for YCANTH.
- Cost Sharing for Trials: Torii will share the costs of the global Phase 3 program with Verrica on a 50/50 basis, with Torii funding the first $40 million of trial costs, ensuring financial support and risk mitigation for the project.
- Significant Market Opportunity: With around 22 million patients suffering from common warts in the U.S. and no FDA-approved therapies available, Verrica anticipates that if YCANTH is successfully developed and commercialized, it could unlock a multibillion-dollar commercial opportunity, particularly in the pediatric market.
See More
Verrica Pharmaceuticals Q1 2026 Earnings Call Highlights
- Market Demand Growth: Verrica Pharmaceuticals reported total revenue of $5 million in Q1 2026, with $4.3 million from U.S. net YCANTH revenue, indicating accelerating market demand for YCANTH, particularly with record dispensed applicator units in March, which enhances the company's competitive position in the market.
- Japanese Market Expansion: YCANTH was successfully launched in Japan in February as a product of Torii Pharmaceutical, marking a significant milestone that not only begins to offset Verrica's clinical costs but also lays the groundwork for future international expansion, demonstrating the company's strategic positioning in global markets.
- Clinical Trial Progress: The company has achieved over 50% enrollment in the first Phase III trial, COVE-2, and plans to initiate the second Phase III trial, COVE-3, by mid-2026, providing strong support for product market approval and boosting investor confidence in the company's pipeline.
- Strong Financial Position: As of March 31, 2026, Verrica had $20.6 million in cash, expected to fund operations into Q1 2027, and despite a GAAP net loss of $9.7 million, the company reported a gross product margin of 87.3%, indicating strong potential for profitability.
See More
Verrica Presents Phase 2 Data for VP-315 Indicating Abscopal Effect in BCC Treatment
- Phase 2 Data Presentation: Verrica Therapeutics presented Phase 2 data for VP-315 at the Society for Investigative Dermatology annual meeting on May 15, 2026, indicating its potential efficacy in treating basal cell carcinoma (BCC), which is the most common cancer in the U.S. with 36 million new cases diagnosed annually.
- Non-Surgical Treatment Option: VP-315, a novel oncolytic peptide immunotherapy, is administered directly to tumors, inducing immunogenic cell death and providing a non-surgical alternative to traditional surgical excisions, thereby reducing patient risks associated with surgery.
- Observed Abscopal Effect: In the Phase 2 open-label study, non-treated lesions (NTLs) showed a 67% reduction in size over 12 weeks, with 21% achieving complete histological clearance, suggesting that VP-315 may trigger an abscopal effect through broader immune activation within the tumor microenvironment.
- Exploration of Multiple Indications: VP-315 is also being investigated for various oncological indications, including non-metastatic melanoma and squamous cell carcinoma, and has demonstrated positive tumor-specific immune cell responses in multi-indication Phase 1/2 trials, enhancing its market potential.
See More
Verrica Pharmaceuticals Reports 2025 Financial Highlights
- Improved Financial Performance: Verrica Pharmaceuticals reported a narrower net loss of $8.07 million for Q4 2025, translating to a loss of $0.57 per share, significantly down from $16.20 million and $2.41 per share a year earlier, indicating a notable improvement in financial health.
- Significant Revenue Growth: Total revenue for 2025 reached $35.57 million, a substantial increase from $7.56 million the previous year, primarily driven by heightened demand for YCANTH, with product revenue soaring 130% from $6.57 million to $15.28 million.
- Market Expansion Plans: Verrica successfully launched YCANTH in Japan in February 2026 and plans to initiate a second Phase 3 study in mid-2026 to further evaluate VP-102 in the US and Japan, demonstrating the company's proactive approach to entering new markets.
- R&D Progress: The company commenced a global Phase 3 program in December 2025 to evaluate YCANTH for treating common warts, based on positive results from the Phase 2 study, showcasing Verrica's ongoing innovation in dermatological treatments.
See More
Verrica Pharmaceuticals Reports Strong 2025 Earnings Growth
- Significant Revenue Growth: Verrica Pharmaceuticals reported total revenue of $35.6 million for 2025, marking a 368% year-over-year increase, demonstrating strong market performance driven by the YCANTH product, which is expected to further enhance market share.
- Effective Cost Management: Although R&D expenses rose to $2.5 million, the company successfully reduced selling, general, and administrative expenses by over 40%, indicating effective strategies in cost management that contribute to improved overall profitability.
- Improved Financial Position: The company secured $18 million in milestone payments from its collaboration with Torii Pharmaceuticals and executed a $50 million equity raise, strengthening its financial stability and expected to support future operations and R&D.
- Market Competition Challenges: Despite growth in YCANTH sales, applicator sales saw a sequential decline of approximately 3% in Q4, reflecting issues with gaps in the sales force that could impact future market performance, necessitating close attention to competitor dynamics.
See More
Verrica Pharmaceuticals Initiates Phase 3 Trial for YCANTH in Common Warts
- Trial Initiation: Verrica Pharmaceuticals announced on Monday the dosing of the first U.S. patient in the Phase 3 COVE-3 trial for YCANTH, marking a significant advancement in treating common warts, potentially benefiting 22 million patients in the U.S.
- International Collaboration: Partner Torii Pharmaceutical initiated dosing for the first Japanese patient in the COVE-3 trial last week, indicating the global development potential of YCANTH and enhancing Verrica's competitive position in the market.
- Trial Design: The COVE-3 trial is a double-blind, randomized, vehicle-controlled study aimed at evaluating the efficacy and safety of YCANTH, following the completion of 50% enrollment in the COVE-2 trial, showcasing the company's proactive approach in clinical development.
- Funding Allocation: The trial expenses will be shared equally between Verrica and Torii, with Torii covering the first $40 million, a collaborative funding strategy that alleviates Verrica's financial burden and supports ongoing R&D efforts.
See More
Verrica Advances Clinical Trials for YCANTH in U.S. and Japan
- Clinical Trial Launch: Verrica announced the dosing of the first patient in the U.S. for the second clinical trial, COVE-3, marking a significant advancement in the global Phase 3 program for YCANTH (VP-102) aimed at treating common warts, which addresses the unmet needs of approximately 22 million patients in the U.S.
- Japanese Patient Enrollment: Verrica's partner, Torii Pharmaceutical, has also dosed the first patient in Japan for the COVE-3 trial, demonstrating synchronized progress in both markets and enhancing the global market potential for YCANTH.
- Cost Sharing for Trials: Torii will share the costs of the global Phase 3 program with Verrica on a 50/50 basis, with Torii funding the first $40 million of trial costs, ensuring financial support and risk mitigation for the project.
- Significant Market Opportunity: With around 22 million patients suffering from common warts in the U.S. and no FDA-approved therapies available, Verrica anticipates that if YCANTH is successfully developed and commercialized, it could unlock a multibillion-dollar commercial opportunity, particularly in the pediatric market.
See More
Verrica Pharmaceuticals Q1 2026 Earnings Call Highlights
- Market Demand Growth: Verrica Pharmaceuticals reported total revenue of $5 million in Q1 2026, with $4.3 million from U.S. net YCANTH revenue, indicating accelerating market demand for YCANTH, particularly with record dispensed applicator units in March, which enhances the company's competitive position in the market.
- Japanese Market Expansion: YCANTH was successfully launched in Japan in February as a product of Torii Pharmaceutical, marking a significant milestone that not only begins to offset Verrica's clinical costs but also lays the groundwork for future international expansion, demonstrating the company's strategic positioning in global markets.
- Clinical Trial Progress: The company has achieved over 50% enrollment in the first Phase III trial, COVE-2, and plans to initiate the second Phase III trial, COVE-3, by mid-2026, providing strong support for product market approval and boosting investor confidence in the company's pipeline.
- Strong Financial Position: As of March 31, 2026, Verrica had $20.6 million in cash, expected to fund operations into Q1 2027, and despite a GAAP net loss of $9.7 million, the company reported a gross product margin of 87.3%, indicating strong potential for profitability.
See More
Verrica Presents Phase 2 Data for VP-315 Indicating Abscopal Effect in BCC Treatment
- Phase 2 Data Presentation: Verrica Therapeutics presented Phase 2 data for VP-315 at the Society for Investigative Dermatology annual meeting on May 15, 2026, indicating its potential efficacy in treating basal cell carcinoma (BCC), which is the most common cancer in the U.S. with 36 million new cases diagnosed annually.
- Non-Surgical Treatment Option: VP-315, a novel oncolytic peptide immunotherapy, is administered directly to tumors, inducing immunogenic cell death and providing a non-surgical alternative to traditional surgical excisions, thereby reducing patient risks associated with surgery.
- Observed Abscopal Effect: In the Phase 2 open-label study, non-treated lesions (NTLs) showed a 67% reduction in size over 12 weeks, with 21% achieving complete histological clearance, suggesting that VP-315 may trigger an abscopal effect through broader immune activation within the tumor microenvironment.
- Exploration of Multiple Indications: VP-315 is also being investigated for various oncological indications, including non-metastatic melanoma and squamous cell carcinoma, and has demonstrated positive tumor-specific immune cell responses in multi-indication Phase 1/2 trials, enhancing its market potential.
See More
Verrica Pharmaceuticals Reports 2025 Financial Highlights
- Improved Financial Performance: Verrica Pharmaceuticals reported a narrower net loss of $8.07 million for Q4 2025, translating to a loss of $0.57 per share, significantly down from $16.20 million and $2.41 per share a year earlier, indicating a notable improvement in financial health.
- Significant Revenue Growth: Total revenue for 2025 reached $35.57 million, a substantial increase from $7.56 million the previous year, primarily driven by heightened demand for YCANTH, with product revenue soaring 130% from $6.57 million to $15.28 million.
- Market Expansion Plans: Verrica successfully launched YCANTH in Japan in February 2026 and plans to initiate a second Phase 3 study in mid-2026 to further evaluate VP-102 in the US and Japan, demonstrating the company's proactive approach to entering new markets.
- R&D Progress: The company commenced a global Phase 3 program in December 2025 to evaluate YCANTH for treating common warts, based on positive results from the Phase 2 study, showcasing Verrica's ongoing innovation in dermatological treatments.
See More
Verrica Pharmaceuticals Reports Strong 2025 Earnings Growth
- Significant Revenue Growth: Verrica Pharmaceuticals reported total revenue of $35.6 million for 2025, marking a 368% year-over-year increase, demonstrating strong market performance driven by the YCANTH product, which is expected to further enhance market share.
- Effective Cost Management: Although R&D expenses rose to $2.5 million, the company successfully reduced selling, general, and administrative expenses by over 40%, indicating effective strategies in cost management that contribute to improved overall profitability.
- Improved Financial Position: The company secured $18 million in milestone payments from its collaboration with Torii Pharmaceuticals and executed a $50 million equity raise, strengthening its financial stability and expected to support future operations and R&D.
- Market Competition Challenges: Despite growth in YCANTH sales, applicator sales saw a sequential decline of approximately 3% in Q4, reflecting issues with gaps in the sales force that could impact future market performance, necessitating close attention to competitor dynamics.
See More
